NCT02552940View on ClinicalTrials.gov

An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

CompletedOBSERVATIONAL
Enrollment

140

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 23, 2017

Study Completion Date

October 23, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tocilizumab

Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.

Trial Locations (22)

1000

CHU St Pierre (César de Paepe), Brussels

1050

HIS (Etterbeek Ixelles), Brussels

1070

Hospital Erasme; Neurologie, Brussels

2390

AZ Sint Jozef Malle, Westmalle

2540

Höpital Kirchberg; Rheumatology, Luxembourg

2610

Sint Augustinus Wilrijk, Wilrijk

2650

UZ Antwerpen, Edegem

2980

CVBA Diagnosecentrum Voorkempen, Zoersel

3600

Reumacentrum Genk, Genk

Reumaclinic, Genk

4000

CHU Sart-Tilman, Liège

5530

CHU UCL Mont-Godinne, Mont-godinne

6000

GHdC Site Saint-Joseph, Gilly (Charleroi)

8000

AZ Sint Jan, Bruges

8310

AZ Sint Lucas Brugge, Assebroek

8340

AZ Alma vzw (Sijsele), Sijsele

8400

AZ Damiaan, Ostend

8500

AZ Groeninge, Kortrijk

9160

Private Practice, Lokeren

9200

AZ Sint Blasius (Dendermonde), Dendermonde

9300

ASZ Aalst, Aalst

9700

AZ Oudenaarde, Oudenaarde

All Listed Sponsors
collaborator

nv Roche sa

UNKNOWN

lead

Hoffmann-La Roche

INDUSTRY

NCT02552940 - An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice | Biotech Hunter | Biotech Hunter